WorldHealth

WHO: Vaccine link to blood clots not established

The WHO Global Advisory Committee on Vaccine Safety (GACVS) Covid-19 subcommittee on safety signals related to the AstraZeneca vaccine said that available data do not suggest any increase in clotting conditions following Covid-19 vaccines.

The subcommittee reviewed clinical trial data and reports based on safety data from Europe, UK, India, and Vigibase.

The subcommittee’s findings and recommendations are:

  • The available data do not suggest any overall increase in clotting conditions such as deep venous thrombosis or pulmonary embolism following Covid-19 vaccines. Reported rates of thromboembolic events after Covid-19 vaccines are in line with the expected number of diagnoses of these conditions. Both conditions occur naturally and are not uncommon. They also occur as a result of Covid-19. The observed rates have been fewer than expected for such events.
  • While very rare and unique thromboembolic events in combination with thrombocytopenia have been reported following vaccination with AstraZeneca in Europe, it is not certain that they have been caused by vaccination. The European Medicines Agency’s Pharmacovigilance and Risk Assessment Committee has reviewed 18 cases of CVST out of a total of more than 20 million vaccinations with the AstraZeneca Covid-19 vaccine in Europe. A causal relationship between these rare events has not been established at this time.
  • Adequate education should be provided to recognize the signs and symptoms of all serious adverse events after Covid-19 vaccinations, so that people may seek and receive prompt and relevant medical care and treatment.
  • Continue to monitor the safety of all Covid-19 vaccines and promote reporting of suspected adverse events.
  • The GACVS subcommittee agrees with the European Medicines Agency’s plans to further investigate and monitor for these events.

Comments

Source
Trade Arabia

Related Articles

Back to top button